Ivabradine Amarox (Ivabradine Hydrochloride)

Ivabradine, the active ingredient in Ivabradine Amarox, is a If channel inhibitor presented as a tablet for oral use. It treats chronic stable angina and heart failure with reduced ejection fraction in adult patients. GNH USA supplies Ivabradine Amarox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradine acts on the cardiac If current to control heart rate in several cardiovascular conditions. Chronic stable angina: reduces the frequency of angina attacks by lowering heart rate. Heart failure with reduced ejection fraction: improves exercise capacity and lowers risk of hospitalization. Inappropriate sinus tachycardia: decreases excessive heart rate when other therapies are unsuitable.

Ivabradine may cause a range of adverse reactions.

Common Side Effects: - Bradycardia: heart rate slower than intended. - Visual disturbances (phosphenes): transient luminous phenomena. - Headache. - Dizziness. - Fatigue. - Nausea.

Serious or Rare Side Effects: - Severe bradycardia requiring medical intervention. - Atrial fibrillation or other arrhythmias. - Symptomatic hypotension. - Persistent visual loss. - Hepatic dysfunction. - Allergic reactions such as rash or angioedema.

Before prescribing Ivabradine, clinicians should consider several safety aspects. - Cardiac monitoring: obtain baseline heart rate and ECG. - Avoid in patients with severe hypotension or sick‑sinus syndrome. - Use caution when combined with other heart‑rate‑lowering agents. - Not recommended for acute decompensated heart failure. - Pregnancy and lactation: safety unknown; prescribe only if benefits outweigh risks. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Ivabradine can interact with several medicines that affect its metabolism or heart‑rate effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may markedly increase plasma concentrations. - Co‑administration with other heart‑rate‑lowering drugs (beta‑blockers, digoxin): risk of excessive bradycardia.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Verapamil: can raise ivabradine levels modestly. - Certain antidepressants that affect CYP3A4 (e.g., fluvoxamine): may require dose adjustment.